top of page


Video testimonials
Case studies

Case studies

PR client

Our clients' newsflow referencing ILife Consulting

ImCheck Therapeutics
March 26, 2020

First Patient Dosed in EVICTION Trial Evaluating ImCheck’s Lead Anti-Cancer Drug, ICT01: A Novel Gamma Delta

T Cell-Activating Immunotherapy

ImCheck Therapeutics
EVICTION study at SITC 2020

Preliminary Results in Solid Tumor Patients with ICT01, a First-in-Class, γ9δ2 T Cell Activating Antibody Targeting Butyrophilin 3A

Smart Immune
Oct 13, 2021

Smart Immune Receives IRB Approval For Phase 1/2 Clinical Trial of Proprietary Allogeneic T-cell Product Smart-101 (ProTcellTM) for AML and ALL
Trial to commence in November 2021

ImCheck Therapeutics
EVICTION-2 study at SITC 2022

Enhancing the Anti-tumor Immunity and Therapeutic Potential of ICT01 a Butyrophilin 3A γ9δ2 T Cell-Activating Monoclonal Antibody with Low Dose IL-2 in Patients with Advanced Solid Tumors

ImCheck Therapeutics
Sept.10, 2020

ImCheck Achieves Initial Positive Independent Safety Review
and Initiates Next Stage of Phase I/IIa EVICTION Trial for ICT01

ImCheck Therapeutics
Nov.11, 2020

ImCheck Presents at SITC First Clinical Demonstration of Gamma Delta T Cell Activation and Tumor Infiltration with Positive Safety for ICT01

ImCheck Therapeutics
November 11, 2022


ImCheck Presents Initial Patient Data from the EVICTION-2 Clinical Trial at SITC Annual Meeting

Testimonials of some of our freelance Clinical Research Associates

Testimonials CRA
bottom of page